VIA EDGAR

August 16, 2013

Jeffrey P. Riedler

Assistant Director

Division of Corporate Finance

U.S. Securities and Exchange Commission

Washington, D.C. 20549

Re:	Cleveland BioLabs, Inc. (File No.: 001-32954)
	SEC Comment Letter dated August 5, 2013

Dear Mr. Riedler:

On behalf of Cleveland BioLabs, Inc. (“CBLI”), we refer to the letter dated August 5, 2013 (the “Letter”) from you relating to CBLI’s Form 10-K for the fiscal year ended December 31, 2012. We will be responding to the Letter on or prior to August 30, 2013.  We believe the additional time is required in order to properly review and finalize the responses.

If you require additional information, please telephone the undersigned at (716) 849-6810.

Sincerely,

/s/ Yakov Kogan

Yakov Kogan, Ph.D., MBA

Chief Executive Officer

Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.  |  73 High Street  |  Buffalo, NY 14203  |  www.cbiolabs.com

P (716) 849-6810  |  F (716) 849-6820